The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients

Table 2

Descriptive data for SV40 expression in DLBCL.

Variables	Positive SV40; (); No (%)	Negative SV40; (); No (%)
Age
± SD	31.0 ± 19.5	55.2 ± 15.4
Median	30.0	56.0
Range	12–51	2–87
<60	1 (2)	48 (98)
≥60	2 (6)	34 (94)
Gender
Male	1 (2)	41 (98)
Female	2 (5)	41 (95)
Primary site of involvement
Nodal	2 (4)	54 (96)
Extranodal	1 (3)	28 (97)
Number of involved extranodal sites
0	1 (2)	46 (98)
1-2	0 (0)	32 (100)
>2	2 (33)	4 (67)
Status
Generalized	2 (12)	14 (88)
Localized	1 (2)	39 (98)
Size (cm)
≤10	2 (3)	72 (97)
>10	1 (9)	10 (91)
Stage grouping
Early	0 (0)	48 (100)
Advanced	3 (8)	34 (92)
PS
<2	0 (0)	14 (100)
≥2	3 (4.2)	68 (95.8)
B symptoms
Present	2 (4)	49 (96)
Absent	1 (3)	33 (97)
LDH
Normal	0 (0)	11 (100)
Elevated	3 (4)	71 (96)
Prognostic group of R-IPI
Good	0 (0)	29 (100)
Poor	3 (5)	53 (95)
Risk groups of AAIPI ≥60
Low	0 (0)	0 (0)
Intermediate	0 (0)	0 (0)
High	2 (14)	0 (0)
Risk groups of AAIPI <60
Low	0 (0)	0 (0)
Intermediate	0 (0)	0 (0)
High	1 (100)	0 (0)
Type of DLBCL
Germinal	2 (4)	47 (96)
Nongerminal	1 (2.8)	35 (97.2)
Necrosis
Present	0 (0)	14 (100)
Absent	3 (14)	68 (96)
± SD	—	34.29 ± 22.43
Range	—	10.0–80.0
Mitosis
± SD	21.3 ± 1.5	22.5 ± 9.7
Range	20–23	6–46
Media	21.0	21.5
Ki-67 LI
<50	3 (4)	74 (96)
≥50	0 (0)	8 (100)
Apoptosis
± SD	12.7 ± 3.1	13.5 ± 6.5
Range	10–16	3–31
Median	12	13

R-IPI: revised international prognostic index; AAIPI: age adjusted international prognostic index.
PS: performance status; LDH: lactate dehydrogenase; Ki-67 LI: Ki-67 labeling index.
DLBCL: diffuse large B-cell lymphoma.